News Release

Shareholder Tools

AmerisourceBergen Reports Third Quarter Fiscal Year 2016 Results

VALLEY FORGE, Pa.--(BUSINESS WIRE)--Aug. 2, 2016--
AmerisourceBergen Corporation (NYSE:ABC) today reported that in its
fiscal year 2016 third quarter ended June 30, 2016, revenue increased
7.7 percent to $36.9 billion. On the basis of U.S. generally accepted
accounting principles (GAAP), diluted earnings per share was $1.56 for
the June quarter of fiscal 2016, an increase of 75.3 percent. Adjusted
diluted earnings per share, which excludes items described below,
increased 14.2 percent to $1.37 in the quarter.

“I am pleased with the solid performance we delivered in the June
quarter,” said Steven H. Collis, Chairman, President and Chief Executive
Officer of AmerisourceBergen. “Our most recent acquisitions, MWI
Veterinary Supply and PharMEDium, have made strong contributions, and
our specialty group delivered excellent performance. We renewed our
relationship with our largest health systems customer for an additional
5 years, and have made progress on our efforts to address the headwinds
we face in AmerisourceBergen Drug Corporation.”

Below we present descriptive summaries of our GAAP quarterly results as
well as our adjusted quarterly results. In the tables that follow, we
present our GAAP results and GAAP to non-GAAP reconciliations. Refer to
the Supplemental Information Regarding Non-GAAP Financial Measures
following the tables.

Summary of GAAP Quarterly Results

Revenue: In the third quarter of fiscal
2016, revenue was $36.9 billion, up 7.7 percent compared to the same
quarter in the previous fiscal year, reflecting an 8.0 percent
increase in Pharmaceutical Distribution revenue, and a 2.8 percent
increase in revenue within Other.

Gross Profit: Gross profit in the fiscal
2016 third quarter was $1.1 billion, a 24.3 percent increase over the
same period in the previous year, driven primarily by an increase in
the gain from antitrust litigation settlements, a decrease in LIFO
expense, and the addition of PharMEDium, which was acquired in
November 2015. Gross profit as a percentage of revenue increased 40
basis points to 3.00 percent from the prior year quarter.

Operating Expenses: In the third quarter
of fiscal 2016, operating expenses were $581.2 million, up 4.0 percent
over the same period in the last fiscal year. Distribution, selling
and administrative expenses increased by $17.3 million compared to the
same period in the last fiscal year, primarily due to our November
2015 acquisition of PharMEDium and additional costs to support the
revenue growth of our businesses, offset in part by the impact of
certain expense reduction initiatives. Operating expenses as a
percentage of revenue in the fiscal 2016 third quarter were 1.58
percent compared to 1.63 percent for the same period in the previous
fiscal year.

Operating Income: In the fiscal 2016
third quarter, operating income of $526.6 million was up 58.3 percent
versus the prior year, driven by the increase in gross profit, which
was offset in part by the increase in operating expenses. Operating
income as a percentage of revenue increased 46 basis points to 1.43
percent in the fiscal 2016 third quarter compared to the previous
year’s third quarter.

Interest Expense, Net:In the
fiscal 2016 third quarter, net interest expense of $32.1 million was
up 7.8 percent versus the prior year quarter due to the increase in
borrowings to partially fund the acquisition of PharMEDium.

Tax Rate: The effective tax rate for the
third quarter of fiscal 2016 was 29.6 percent, flat compared to the
previous fiscal year’s third quarter.

Earnings Per Share: Diluted earnings per
share was up 75.3 percent to $1.56 in the third quarter of fiscal year
2016 compared to $0.89 in the previous fiscal year’s third quarter,
driven primarily by the increase in net income.

Shares Outstanding: Diluted weighted
average shares outstanding for the third quarter of fiscal year 2016
were 224.8 million, a 6.4 percent decline versus the prior year
quarter due to share repurchases, net of the 2016 Warrants and stock
option exercises.

Definition of Adjusted Results

The comments below compare adjusted results, which exclude:

Warrants (income) expense;

Gain from antitrust litigation settlements;

LIFO expense;

Acquisition-related intangibles amortization;

Employee severance, litigation and other expenses; and a

Pension settlement.

In addition, we calculate our adjusted earnings per share for each
period using a diluted weighted average share count, which excludes the
accounting dilution resulting from the impact of the unexercised equity
warrants, and the impact from the shares repurchased under our special
share repurchase programs, net of the weighted average number of shares
issued related to the March 2016 warrant exercise. We previously issued
$600 million of 1.15% senior notes due in May 2017 to fund our initial
special share repurchase program. The interest expense incurred relating
to this borrowing is also excluded from the non-GAAP presentation.

Summary of Adjusted Quarterly Results

Revenue: In the third quarter of fiscal
2016, revenue was $36.9 billion, up 7.7 percent compared to the same
quarter in the previous fiscal year, reflecting an 8.0 percent
increase in Pharmaceutical Distribution revenue, and a 2.8 percent
increase in revenue within Other.

Adjusted Gross Profit: Gross profit in
the fiscal 2016 third quarter was $1.1 billion, a 6.0 percent increase
over the same period in the previous year, driven primarily by the
addition of PharMEDium and the increase in revenue. Gross profit as a
percentage of revenue decreased 5 basis points to 2.89 percent from
the prior year quarter.

Adjusted Operating Expenses: In the third
quarter of fiscal 2016, operating expenses were $574.0 million, up 4.1
percent over the same period in the last fiscal year. The increase in
operating expenses in the quarter was primarily driven by the addition
of PharMEDium and additional costs to support the revenue growth of
our businesses, offset in part by the impact of certain expense
reduction initiatives. Operating expenses as a percentage of revenue
in the fiscal 2016 third quarter were 1.56 percent, compared to 1.61
percent for the same period in the previous fiscal year.

Adjusted Operating Income: In the fiscal
2016 third quarter, operating income of $493.2 million was up 8.4
percent versus the prior year, driven by the increase in gross profit,
which was offset in part by the increase in operating expenses.
Operating income as a percentage of revenue increased 1 basis point to
1.34 percent in the fiscal 2016 third quarter compared to the previous
year’s third quarter.

Adjusted Interest Expense, Net:In
the fiscal 2016 third quarter, net interest expense of $30.0 million
was up 8.4 percent versus the prior year quarter due to the increase
in borrowings to partially fund the acquisition of PharMEDium.

Adjusted Tax Rate: The effective tax rate
for the third quarter of fiscal 2016 was 32.8 percent, down from 35.3
percent in the previous fiscal year’s third quarter, reflecting a rate
benefit resulting from the favorable impact of growth in our
international businesses.

Adjusted Earnings Per Share: Diluted
earnings per share was up 14.2 percent to $1.37 in the third quarter
of fiscal year 2016 compared to $1.20 in the previous fiscal year’s
third quarter, driven primarily by the increase in income before taxes
and the lower effective tax rate.

Adjusted Shares Outstanding: Diluted
weighted average shares outstanding for the third quarter of fiscal
year 2016 were 228.6 million, a 1 percent decline versus the prior
year quarter.

Segment Discussion

The Pharmaceutical Distribution segment includes both AmerisourceBergen
Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG).
PharMEDium is a component of ABDC. Other includes AmerisourceBergen
Consulting Services (ABCS), World Courier, and MWI Veterinary Supply
(MWI).

Pharmaceutical Distribution Segment

Pharmaceutical Distribution revenue was $35.4 billion, an increase of
8.0 percent compared to the same quarter in the prior year. ABDC’s
revenue increased 6.5 percent, due primarily to solid organic sales
growth including sales to Walgreens Boots Alliance, Inc. ABSG’s revenue
increased 20.2 percent, which was driven by strong performance in our
third party logistics business, in our oncology business (including an
increase in sales to community oncologists), and by sales growth in our
blood products, vaccine and physician office distribution businesses.
Intrasegment revenues between ABDC and ABSG have been eliminated in the
presentation of total Pharmaceutical Distribution revenue. Total
intrasegment revenues were $2.0 billion and $1.6 billion in the quarters
ended June 30, 2016 and 2015, respectively.

Segment operating income of $410.7 million in the June quarter of fiscal
2016 was up 8.7 percent compared to the same period in the previous year
due to the addition of PharMEDium and strong performance in ABSG, offset
in part by the impact of previously announced customer renewals in ABDC.

Other

Revenue in Other was $1.6 billion in the third quarter of fiscal 2016,
an increase of 2.8 percent over the same period in the prior year as
good performance in MWI and World Courier was offset by a decline in
ABCS revenue. Operating income in Other increased 6.6 percent to $82.5
million in the third quarter of fiscal 2016, primarily driven by strong
performance of MWI.

Fiscal Year 2016 Expectations on an Adjusted
Basis

Looking ahead, we continue to expect our gross profit in the fourth
quarter to be negatively impacted by the headwinds we identified in
early May, but with the performance we achieved in the June quarter, we
now expect fiscal year 2016 adjusted diluted earnings per share to be in
the range of $5.52 to $5.57.

The Company continues to expect:

Revenue growth of approximately 8 percent;

Operating income growth in the range of 5 percent to 6 percent;

Effective tax rate of approximately 33 percent;

Free cash flow generation in the range of $1.9 billion to $2.1
billion; and

Capital expenditures in the $400 million range.

In addition, we now expect total share repurchases under our regular
programs of approximately $350 million, as well as special share
repurchases to satisfy previously disclosed hedging programs, all
subject to market conditions.

Preliminary Fiscal Year 2017 Expectations on an
Adjusted Basis

The Company also continues to expect that the headwinds that are
impacting our fiscal 2016 will continue well into fiscal 2017, including
a rate of deflation on generic products in the high single digit range.
Adjusted diluted earnings per share in fiscal year 2017 is expected to
grow in the range of 4 percent to 6 percent above the midpoint of our
updated fiscal 2016 guidance. This expectation, as well as the other
assumptions below, does not include any potential benefit from a change
in the accounting for the excess tax benefits relating to share-based
compensation, or any potential negative impact from proposed changes to
reimbursement mechanisms under Medicare Part B.

Other assumptions underlying the preliminary expectations for financial
performance in fiscal 2017 include:

The dial-in number for the live call will be (612) 326-1003. No access
code is required. The live call will also be webcast via the Company’s
website at www.amerisourcebergen.com.
Users are encouraged to log on to the webcast approximately 10 minutes
in advance of the scheduled start time of the call.

Replays of the call will be made available via telephone and webcast. A
replay of the webcast will be posted on www.amerisourcebergen.com
approximately two hours after the completion of the call and will remain
available for thirty days. The telephone replay will also be available
approximately two hours after the completion of the call and will remain
available for seven days. To access the telephone replay from within the
US, dial (800) 475-6701. From outside the US, dial (320) 365-3844. The
access code for the replay is 397127.

Upcoming Investor Events

AmerisourceBergen management will be attending the following investor
conferences in September:

Robert W. Baird Healthcare Conference on September 7, 2016, and

Morgan Stanley Global Healthcare Conference on September 13, 2016.

Please check the website for updates regarding the timing of the live
presentation webcasts, if any, and for replay information.

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing
and distribution services companies, helping both healthcare providers
and pharmaceutical and biotech manufacturers improve patient access to
products and enhance patient care. With services ranging from drug
distribution and niche premium logistics to reimbursement and
pharmaceutical consulting services, AmerisourceBergen delivers
innovative programs and solutions across the pharmaceutical supply
channel in human and animal health. With over $140 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 19,000 people. AmerisourceBergen is ranked #12 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as "expect," "likely," "outlook," "forecast," "would,"
"could," "should," "can," "will," "project," "intend," "plan,"
"continue," "sustain," "synergy," "on track," "believe," "seek,"
"estimate," "anticipate," "may," "possible," "assume," variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management's
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: competition;
industry consolidation of both customers and suppliers resulting in
increasing pressure to reduce prices for our products and services;
changes in pharmaceutical market growth rates; price inflation in
branded and generic pharmaceuticals, and price deflation in generics;
declining economic conditions in the United States and abroad; financial
market volatility and disruption; substantial defaults in payment,
material reduction in purchases by or the loss, bankruptcy or insolvency
of a major customer; the loss, bankruptcy or insolvency of a major
supplier; changes to the customer or supplier mix; the retention of key
customer or supplier relationships under less favorable economics or the
adverse resolution of any contract or other dispute with customers or
suppliers; changes to customer or supplier payment terms; changes in any
of the economic models used by any of our suppliers to set pricing
and/or other terms for the purchase of pharmaceuticals; interest rate
and foreign currency exchange rate fluctuations; the disruption of
AmerisourceBergen's cash flow and ability to return value to its
stockholders in accordance with its past practices; risks associated
with the strategic, long-term relationship between Walgreens Boots
Alliance, Inc. and AmerisourceBergen, including with respect to the
pharmaceutical distribution agreement and/or the global sourcing
arrangement; risks associated with the potential impact on
AmerisourceBergen's earnings per share resulting from the issuance of
the warrants to subsidiaries of Walgreens Boots Alliance, Inc. (the
"Warrants"); AmerisourceBergen's inability to fully implement its
hedging strategy to mitigate the potentially dilutive effect of the
issuance of its common stock in accordance with the Warrants under its
special share repurchase program due to its financial performance, the
current and future share price of its common stock, its expected cash
flows, competing priorities for capital, and overall market conditions;
changes in the United States healthcare and regulatory environment,
including changes that could impact prescription drug reimbursement
under Medicare and Medicaid; increasing governmental regulations
regarding the pharmaceutical supply channel and pharmaceutical
compounding; federal and state government enforcement initiatives to
detect and prevent suspicious orders of controlled substances and the
diversion of controlled substances; federal and state prosecution of
alleged violations of related laws and regulations, and any related
litigation, including shareholder derivative lawsuits or other disputes
relating to our distribution of controlled substances; increased federal
scrutiny and qui tam litigation for alleged violations of fraud and
abuse laws and regulations and/or any other laws and regulations
governing the marketing, sale, purchase and/or dispensing of
pharmaceutical products or services and any related litigation; material
adverse resolution of pending legal proceedings; declining reimbursement
rates for pharmaceuticals; the acquisition of businesses that do not
perform as expected, or that are difficult to integrate or control,
including the integration of MWI and PharMEDium, or the inability to
capture all of the anticipated synergies related thereto; managing
foreign expansion, including non-compliance with the U.S. Foreign
Corrupt Practices Act, anti-bribery laws and economic sanctions and
import laws and regulations; malfunction, failure or breach of
sophisticated information systems to operate as designed; risks
generally associated with data privacy regulation and the international
transfer of personal data; changes in tax laws or legislative
initiatives that could adversely affect AmerisourceBergen's tax
positions and/or AmerisourceBergen's tax liabilities or adverse
resolution of challenges to AmerisourceBergen's tax positions; natural
disasters or other unexpected events that affect AmerisourceBergen's
operations; the impairment of goodwill or other intangible assets,
resulting in a charge to earnings; errors in the production, labeling or
packaging of products compounded by our compounded sterile preparations
(CSP) business; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors affecting AmerisourceBergen's
business generally. Certain additional factors that management believes
could cause actual outcomes and results to differ materially from those
described in forward-looking statements are set forth (i) in Item 1A
(Risk Factors) in the Company’s Annual Report on Form 10-K for the
fiscal year ended September 30, 2015 and elsewhere in that report and
(ii) in other reports filed by the Company pursuant to the Securities
Exchange Act.

AMERISOURCEBERGEN CORPORATION

FINANCIAL SUMMARY

(In thousands, except per share data)

(unaudited)

Three

Three

Months Ended

Months Ended

June 30,

% of

June 30,

% of

%

2016

Revenue

2015

Revenue

Change

Revenue

$36,881,680

$34,233,556

7.7

%

Cost of goods sold

35,773,817

33,342,092

7.3

%

Gross profit (1)

1,107,863

3.00

%

891,464

2.60

%

24.3

%

Operating expenses:

Distribution, selling and administrative

520,032

1.41

%

502,744

1.47

%

3.4

%

Depreciation and amortization

92,687

0.25

%

68,430

0.20

%

35.4

%

Warrants

(83,704

)

(14,900

)

Employee severance, litigation and other (2)

52,234

2,625

Total operating expenses

581,249

1.58

%

558,899

1.63

%

Operating income

526,614

1.43

%

332,565

0.97

%

58.3

%

Other income

(2,158

)

(1,534

)

Interest expense, net

32,115

29,793

7.8

%

Income before income taxes

496,657

1.35

%

304,306

0.89

%

63.2

%

Income tax expense

146,854

90,143

62.9

%

Net income

$349,803

0.95

%

$214,163

0.63

%

63.3

%

Earnings per share:

Basic

$1.62

$0.98

65.3

%

Diluted

$1.56

$0.89

75.3

%

Weighted average common shares outstanding:

Basic

215,688

219,359

-1.7

%

Diluted

224,802

240,236

-6.4

%

(1)

Includes $121.0 million gain from antitrust litigation settlements
and an $80.4 million LIFO expense charge in the three months ended
June 30, 2016. Includes a $158.7 million LIFO expense charge and
$43.6 million gain from antitrust litigation settlements in the
three months ended June 30, 2015.

(2)

Includes $34.6 million of employee severance and other costs, a
$17.1 million charge related to the transfer of surplus assets
from the Company's settled salaried defined benefit pension plan
to its defined contribution 401(k) plan, and $0.5 million of
deal-related transaction costs in the three months ended June 30,
2016. Includes $2.3 million of deal-related transaction costs and
$0.4 million of employee severance and other costs in the three
months ended June 30, 2015.

AMERISOURCEBERGEN CORPORATION

FINANCIAL SUMMARY

(In thousands, except per share data)

(unaudited)

Nine

Nine

Months Ended

Months Ended

June 30,

% of

June 30,

% of

%

2016

Revenue

2015

Revenue

Change

Revenue

$109,289,083

$100,491,425

8.8

%

Cost of goods sold

106,141,012

97,935,686

8.4

%

Gross profit (1)

3,148,071

2.88

%

2,555,739

2.54

%

23.2

%

Operating expenses:

Distribution, selling and administrative

1,571,088

1.44

%

1,361,678

1.36

%

15.4

%

Depreciation and amortization

265,437

0.24

%

173,932

0.17

%

52.6

%

Warrants

(120,275

)

1,109,211

Employee severance, litigation and other (2)

88,719

30,999

Pension settlement

47,607

-

Total operating expenses

1,852,576

1.70

%

2,675,820

2.66

%

Operating income (loss)

1,295,495

1.19

%

(120,081

)

-0.12

%

Other (income) loss

(3,224

)

11,185

Interest expense, net

96,107

70,081

37.1

%

Income (loss) before income taxes

1,202,612

1.10

%

(201,347

)

-0.20

%

Income tax (benefit) expense

(81,703

)

297,827

Net income (loss)

$1,284,315

1.18

%

($499,174

)

-0.50

%

Earnings per share:

Basic

$6.12

($2.27

)

Diluted

$5.69

($2.27

)

Weighted average common shares outstanding:

Basic

209,898

219,689

-4.5

%

Diluted (3)

225,646

219,689

2.7

%

(1)

Includes a $274.3 million LIFO expense charge and $133.8 million
gain from antitrust litigation settlements in the nine months
ended June 30, 2016. Includes a $453.9 million LIFO expense charge
and $65.1 million gain from antitrust litigation settlements in
the nine months ended June 30, 2015.

(2)

Includes $40.2 million of employee severance and other costs,
$18.3 million of deal-related transaction costs (primarily related
to professional fees with respect to the PharMEDium acquisition),
a $17.1 million charge related to the transfer of surplus assets
from the Company's settled salaried defined benefit pension plan
to its defined contribution 401(k) plan, and $13.0 million of
costs related to customer contract extensions (primarily related
to the settlement of certain disputed items) in the nine months
ended June 30, 2016. Includes $29.6 million of deal-related
transaction costs (primarily related to professional fees with
respect to the MWI acquisition) and $1.4 million of employee
severance and other costs in the nine months ended June 30, 2015.

(3)

As a result of the net loss in the nine months ended June 30,
2015, stock options, restricted stock, restricted stock units and
the Warrants issued to Walgreens Boots Alliance, Inc. were
anti-dilutive.

AMERISOURCEBERGEN CORPORATION

GAAP TO NON-GAAP RECONCILIATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended June 30, 2016

Gross Profit

OperatingExpenses

OperatingIncome

InterestExpense, Net

Income BeforeIncome Taxes

Income TaxExpense

Net Income

DilutedEarnings PerShare

GAAP

$

1,107,863

$

581,249

$

526,614

$

32,115

$

496,657

$

146,854

$

349,803

$

1.56

Warrants income (1)

-

83,704

(83,704

)

(2,155

)

(81,549

)

(29,709

)

(51,840

)

(0.25

)

Gain from antitrust litigation settlements

(120,960

)

-

(120,960

)

-

(120,960

)

(47,979

)

(72,981

)

(0.32

)

LIFO expense

80,364

-

80,364

-

80,364

40,618

39,746

0.17

Acquisition-related intangibles amortization

-

(38,681

)

38,681

-

38,767

18,484

20,283

0.09

Employee severance, litigation and other

-

(52,234

)

52,234

-

52,234

22,177

30,057

0.13

Pension settlement

-

-

-

-

-

2,243

(2,243

)

(0.01

)

Adjusted Non-GAAP

$

1,067,267

$

574,038

$

493,229

$

29,960

$

465,513

$

152,688

$

312,825

$

1.37

Adjusted Non-GAAP % changes vs. prior year quarter

6.0

%

4.1

%

8.4

%

8.4

%

8.4

%

0.6

%

12.7

%

14.2

%

Percentages of Revenue:

GAAP

AdjustedNon-GAAP

Gross profit

3.00

%

2.89

%

Operating expenses

1.58

%

1.56

%

Operating income

1.43

%

1.34

%

(1) A tax expense of approximately $31 million was
recognized primarily related to the change in the fair value of
the Warrants during the three months ended June 30, 2016. In
connection with the fiscal 2014 special $650 million share
repurchase program, the Company issued $600 million of 1.15%
senior notes due in May 2017. The interest expense incurred
relating to this borrowing has been excluded from the non-GAAP
presentation.

Note: For more information related to non-GAAP financial measures,
refer to the section titled "Supplemental Information Regarding
Non-GAAP Financial Measures" of this release.

AMERISOURCEBERGEN CORPORATION

GAAP TO NON-GAAP RECONCILIATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended June 30, 2015

Gross Profit

OperatingExpenses

OperatingIncome

InterestExpense, Net

Income BeforeIncome Taxes

Income TaxExpense

Net Income

DilutedEarnings PerShare

GAAP

$

891,464

$

558,899

$

332,565

$

29,793

$

304,306

$

90,143

$

214,163

$

0.89

Warrants income (1)

-

14,900

(14,900

)

(2,159

)

(12,741

)

7,170

(19,911

)

(0.05

)

Gain from antitrust litigation settlements

(43,567

)

-

(43,567

)

-

(43,567

)

(17,076

)

(26,491

)

(0.11

)

LIFO expense

158,710

-

158,710

-

158,710

62,823

95,887

0.41

Acquisition-related intangibles amortization

-

(19,710

)

19,710

-

19,941

7,831

12,110

0.05

Employee severance, litigation and other

-

(2,625

)

2,625

-

2,625

856

1,769

0.01

Adjusted Non-GAAP

$

1,006,607

$

551,464

$

455,143

$

27,634

$

429,274

$

151,747

$

277,527

$

1.20

Percentages of Revenue:

GAAP

AdjustedNon-GAAP

Gross profit

2.60

%

2.94

%

Operating expenses

1.63

%

1.61

%

Operating income

0.97

%

1.33

%

(1) During the three months ended June 30, 2015, the
amount of Warrants expense deductible for income tax purposes was
based on the initial 2013 valuation of the Warrants. In connection
with the fiscal 2014 special $650 million share repurchase
program, the Company issued $600 million of 1.15% senior notes due
in May 2017. The interest expense incurred relating to this
borrowing has been excluded from the non-GAAP presentation.

Note: For more information related to non-GAAP financial measures,
refer to the section titled "Supplemental Information Regarding
Non-GAAP Financial Measures" of this release.

AMERISOURCEBERGEN CORPORATION

GAAP TO NON-GAAP RECONCILIATIONS

(in thousands, except per share data)

(unaudited)

Nine Months Ended June 30, 2016

Gross Profit

OperatingExpenses

OperatingIncome

InterestExpense, Net

Income BeforeIncome Taxes

Income Tax(Benefit)Expense

Net Income

DilutedEarnings PerShare

GAAP

$

3,148,071

$

1,852,576

$

1,295,495

$

96,107

$

1,202,612

($81,703

)

$

1,284,315

$

5.69

Warrants income (1)

-

120,275

(120,275

)

(6,464

)

(113,811

)

414,273

(528,084

)

$

(2.39

)

Gain from antitrust litigation settlements

(133,758

)

-

(133,758

)

-

(133,758

)

(52,389

)

(81,369

)

$

(0.36

)

LIFO expense

274,305

-

274,305

-

274,305

107,438

166,867

$

0.73

Acquisition-related intangibles amortization

-

(108,611

)

108,611

-

108,801

42,614

66,187

$

0.29

Employee severance, litigation and other

-

(88,719

)

88,719

-

88,719

34,748

53,971

$

0.24

Pension settlement

-

(47,607

)

47,607

-

47,607

18,646

28,961

$

0.13

Adjusted Non-GAAP

$

3,288,618

$

1,727,914

$

1,560,704

$

89,643

$

1,474,475

$

483,627

$

990,848

$

4.32

(2)

Adjusted Non-GAAP % changes vs. prior year period

11.7

%

15.1

%

8.1

%

40.9

%

7.7

%

-2.6

%

13.5

%

14.0

%

Percentages of Revenue:

GAAP

AdjustedNon-GAAP

Gross profit

2.88

%

3.01

%

Operating expenses

1.70

%

1.58

%

Operating income

1.19

%

1.43

%

(1) The Company received a private letter ruling from
the Internal Revenue Service in November 2015, which entitles it
to an income tax deduction equal to the fair value of the Warrants
on the date of exercise. As a result, the Company recognized a tax
benefit adjustment of approximately $456 million, which
represented the estimated tax deduction for the increase in the
fair value of the Warrants from the issuance date through
September 30, 2015. A tax expense of approximately $44 million was
recognized primarily related to the change in the fair value of
the Warrants during the nine months ended June 30, 2016. In
connection with the fiscal 2014 special $650 million share
repurchase program, the Company issued $600 million of 1.15%
senior notes due in May 2017. The interest expense incurred
relating to this borrowing has been excluded from the non-GAAP
presentation.

(2) The sum of the components does not equal the total
due to rounding.

Note: For more information related to non-GAAP financial measures,
refer to the section titled "Supplemental Information Regarding
Non-GAAP Financial Measures" of this release.

AMERISOURCEBERGEN CORPORATION

GAAP TO NON-GAAP RECONCILIATIONS

(in thousands, except per share data)

(unaudited)

Nine Months Ended June 30, 2015

Gross Profit

OperatingExpenses

Operating(Loss)Income

InterestExpense, Net

(Loss) IncomeBefore IncomeTaxes

Income TaxExpense

Net (Loss)Income

DilutedEarnings PerShare

GAAP

$

2,555,739

$

2,675,820

($120,081

)

$

70,081

($201,347

)

$

297,827

($499,174

)

$

(2.27

)

Warrants expense (1)

-

(1,109,211

)

1,109,211

(6,459

)

1,115,670

21,468

1,094,202

4.86

Gain from antitrust litigation settlements

(65,050

)

-

(65,050

)

-

(65,050

)

(25,403

)

(39,647

)

(0.17

)

LIFO expense

453,878

-

453,878

-

453,878

177,249

276,629

1.20

Acquisition-related intangibles amortization

-

(34,478

)

34,478

-

35,279

13,777

21,502

0.09

Employee severance, litigation and other

-

(30,999

)

30,999

-

30,999

11,774

19,225

0.08

Adjusted Non-GAAP

$

2,944,567

$

1,501,132

$

1,443,435

$

63,622

$

1,369,429

$

496,692

$

872,737

$

3.79

Percentages of Revenue:

GAAP

AdjustedNon-GAAP

Gross profit

2.54

%

2.93

%

Operating expenses

2.66

%

1.49

%

Operating income

-0.12

%

1.44

%

(1) During the nine months ended June 30, 2015, the
amount of Warrants expense deductible for income tax purposes was
based on the initial 2013 valuation of the Warrants. In connection
with the fiscal 2014 special $650 million share repurchase
program, the Company issued $600 million of 1.15% senior notes due
in May 2017. The interest expense incurred relating to this
borrowing has been excluded from the non-GAAP presentation.

Note: For more information related to non-GAAP financial measures,
refer to the section titled "Supplemental Information Regarding
Non-GAAP Financial Measures" of this release.

AMERISOURCEBERGEN CORPORATION

RECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
(GAAP TO NON-GAAP)

(1) For the non-GAAP presentation, diluted weighted
average common shares outstanding have been adjusted to exclude
the impact of the unexercised Warrants and the shares repurchased
under special share repurchase programs, net of the weighted
average number of shares issued related to the March 2016 Warrants
exercise.

(2) For the non-GAAP presentation, diluted weighted
average common shares outstanding have been adjusted to include
the impact of the stock options, restricted stock, and restricted
stock units that were anti-dilutive for the GAAP presentation due
to the GAAP loss in the nine months ended June 30, 2015.

Note: For more information related to non-GAAP financial measures,
refer to the section titled "Supplemental Information Regarding
Non-GAAP Financial Measures" of this release.

AMERISOURCEBERGEN CORPORATION

WARRANTS COVERAGE INFORMATION

(In thousands)

(unaudited)

2017 Warrants Exercisable

22,697

Shares repurchased under special share repurchase programs through
June 30, 2016

Adjustments include non-cash Warrants (income) expense of ($120.3)
million and $1,109.2 million for the nine months ended June 30,
2016 and 2015, respectively.

(2)

Merchandise inventories include LIFO expense of $274.3 million and
$453.9 million for the nine months ended June 30, 2016 and 2015,
respectively.

(3)

Includes purchases made under special share repurchase programs
totaling $820.0 million that cash settled in the nine months ended
June 30, 2016 (all under the call options). Includes purchases
made under special share repurchase programs totaling $555.7
million in the nine months ended June 30, 2015, which includes
$18.0 million of fiscal 2014 purchases that cash settled in
October 2014. Additional purchases made in June 2015 under the
special share repurchase programs totaling $14.3 million cash
settled in July 2015.

The non-GAAP financial measures are presented because management uses
non-GAAP financial measures to evaluate the Company’s operating
performance, to perform financial planning, and to determine incentive
compensation. Therefore, the Company believes that the presentation of
non-GAAP financial measures provides useful supplementary information
to, and facilitates additional analysis by, investors. The presented
non-GAAP financial measures exclude items that management does not
believe reflect the Company's core operating performance. The non-GAAP
financial measures should be viewed in addition to, and not in lieu of,
financial measures calculated in accordance with GAAP.

The Company does not provide forward-looking diluted earnings per share
guidance on a GAAP basis as certain financial information is not
available and cannot be reasonably estimated. For example, the expense
or income we recognize related to Warrants is largely dependent on
future changes in our stock price, which are out of the Company’s
control and cannot be reasonably estimated. Additionally, our LIFO
expense is largely dependent upon the future inflation or deflation of
brand and generic pharmaceuticals, which is out of the Company’s control
and cannot be predicted with any reasonable certainty. For the same
reasons, the Company is unable to address the probable significance of
the unavailable information.

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..